Immunic Inc (IMUX)

$0.69 +0.04 (5.89%)
Market Cap 78.19M
Revenue (ttm) 0.00
Net Income (ttm) -100.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,054,300
Avg Vol 1,415,702
Day's Range N/A - N/A
Shares Out 120.29M
Stochastic %K 60%
Beta 1.48
Analysts Strong Sell
Price Target $5.53

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
stonedbunny
stonedbunny Dec. 4 at 10:17 PM
$IMUX Basura
0 · Reply
BoomJBoomJ
BoomJBoomJ Dec. 4 at 9:29 PM
$IMUX old article, 3 and 4 don’t apply here… https://www.griproom.com/fun/12-signs-your-stock-is-targeted-for-buyout-theft
1 · Reply
Mattjen
Mattjen Dec. 4 at 8:59 PM
$IMUX looking beautiful. There’s something special about investing in a company working to improve the lives of those suffering from MS — it feels good on more than just a financial level.
0 · Reply
rizmanasjr
rizmanasjr Dec. 4 at 7:12 PM
$IMUX Enjoy the long drive🚀2026
0 · Reply
Mattjen
Mattjen Dec. 4 at 7:06 PM
$IMUX 2026 will be a good year for IMUX!
0 · Reply
takingstock73
takingstock73 Dec. 4 at 7:02 PM
$IMUX agree, good bullish sentiment on that
0 · Reply
gertje1954
gertje1954 Dec. 4 at 6:49 PM
$IMUX thx
0 · Reply
Johnnyb1973
Johnnyb1973 Dec. 4 at 6:31 PM
$IMUX
0 · Reply
cbowers8171
cbowers8171 Dec. 4 at 6:14 PM
Take a listen for yourself. Definitely Bullish $IMUX https://wsw.com/webcast/evercore52/register.aspx?conf=evercore52&page=imux&url=https://wsw.com/webcast/evercore52/imux/2401190
1 · Reply
gertje1954
gertje1954 Dec. 4 at 6:08 PM
$IMUX @cbowers any new information?
1 · Reply
Latest News on IMUX
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 26, 2025, 6:30 AM EST - 9 days ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:30 AM EST - 22 days ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Oct 29, 2025, 6:30 AM EDT - 5 weeks ago

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

Oct 1, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 25, 2025, 6:30 AM EDT - 2 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 3 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic to Participate in Investor and Scientific Conferences in September

Sep 4, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Immunic (IMUX) Q2 Loss Widens 25%

Aug 7, 2025, 7:48 AM EDT - 4 months ago

Immunic (IMUX) Q2 Loss Widens 25%

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 4 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 5 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 9, 2025, 5:51 PM EDT - 6 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 6 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 6 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 6 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 6 months ago

Immunic, Inc. Announces Proposed Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 28, 2025, 2:09 AM EDT - 7 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 8 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 8 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 8 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 9 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 10 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 10 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 10 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 11 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic to Participate in Industry and Scientific Conferences in June

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in May

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

stonedbunny
stonedbunny Dec. 4 at 10:17 PM
$IMUX Basura
0 · Reply
BoomJBoomJ
BoomJBoomJ Dec. 4 at 9:29 PM
$IMUX old article, 3 and 4 don’t apply here… https://www.griproom.com/fun/12-signs-your-stock-is-targeted-for-buyout-theft
1 · Reply
Mattjen
Mattjen Dec. 4 at 8:59 PM
$IMUX looking beautiful. There’s something special about investing in a company working to improve the lives of those suffering from MS — it feels good on more than just a financial level.
0 · Reply
rizmanasjr
rizmanasjr Dec. 4 at 7:12 PM
$IMUX Enjoy the long drive🚀2026
0 · Reply
Mattjen
Mattjen Dec. 4 at 7:06 PM
$IMUX 2026 will be a good year for IMUX!
0 · Reply
takingstock73
takingstock73 Dec. 4 at 7:02 PM
$IMUX agree, good bullish sentiment on that
0 · Reply
gertje1954
gertje1954 Dec. 4 at 6:49 PM
$IMUX thx
0 · Reply
Johnnyb1973
Johnnyb1973 Dec. 4 at 6:31 PM
$IMUX
0 · Reply
cbowers8171
cbowers8171 Dec. 4 at 6:14 PM
Take a listen for yourself. Definitely Bullish $IMUX https://wsw.com/webcast/evercore52/register.aspx?conf=evercore52&page=imux&url=https://wsw.com/webcast/evercore52/imux/2401190
1 · Reply
gertje1954
gertje1954 Dec. 4 at 6:08 PM
$IMUX @cbowers any new information?
1 · Reply
cbowers8171
cbowers8171 Dec. 4 at 5:44 PM
$IMUX not going to lie, that fireside chat this morning was by far the best I've heard from vitt and Tardio. Hope we can ride the momentum.
2 · Reply
Cattitude
Cattitude Dec. 4 at 5:40 PM
$IMUX any word about this morning? 🤔
1 · Reply
Fillorkill7
Fillorkill7 Dec. 4 at 5:34 PM
$IMUX IMU-838 very positive
0 · Reply
Jw242
Jw242 Dec. 4 at 5:29 PM
$IMUX did we bottom? 🤪
0 · Reply
Mattjen
Mattjen Dec. 4 at 5:01 PM
$IMUX bought the dip. It's going to be rocky, but I know phase 3 data is going to boom!
0 · Reply
Tradergrows
Tradergrows Dec. 4 at 4:19 PM
$IMUX Imagine sitting down with big pharma and saying “yeah that’s not enough zeros, we have competing options or we can do it on our own.”
0 · Reply
Jw242
Jw242 Dec. 4 at 3:30 PM
$IMUX partnership smartnership
0 · Reply
Mvvh1987
Mvvh1987 Dec. 4 at 1:50 PM
$IMUX 🚀 What’s next for Immunic? Find out TODAY when our CEO, Dr. Daniel Vitt, speaks at the @Evercore ISI Healthcare Conference. The fireside chat starts at 9:35 AM ET.
0 · Reply
Whyasking
Whyasking Dec. 4 at 9:42 AM
$IMUX ladies and gentelmen we are done
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Dec. 4 at 3:04 AM
$IMUX at least the warrants are under water too!
1 · Reply
takingstock73
takingstock73 Dec. 4 at 2:26 AM
$IMUX bought more today , reversal coming
0 · Reply
Tradergrows
Tradergrows Dec. 3 at 9:29 PM
$IMUX
0 · Reply